Literature DB >> 20626337

Current place of beta-blockers in the treatment of hypertension.

Agata Bielecka-Dabrowa1, Wilbert S Aronow, Jacek Rysz, Maciej Banach.   

Abstract

Hypertension represents the most common cardiovascular risk factor, affecting more than 25% of the adult population in developed societies. Although beta-blockers have been previously shown to effectively reduce blood pressure and have been used for hypertension treatment for over 40 years, their effect on cardiovascular morbidity and mortality in hypertensive patients remains controversial and their use in uncomplicated hypertension is currently still under debate. According to the previous recommendations beta-blockers should not be preferred as first-line therapy in hypertension patients. This review summarizes the current knowledge on application of beta-blockers in patients with hypertension and discusses the most recent guidelines of the European Society of Hypertension (2009) on beta-blockers applications.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20626337     DOI: 10.2174/157016110793563861

Source DB:  PubMed          Journal:  Curr Vasc Pharmacol        ISSN: 1570-1611            Impact factor:   2.719


  12 in total

1.  Should β blockers no longer be considered first-line therapy for the treatment of essential hypertension without comorbidities?

Authors:  William J Elliott; W Kurtis Childers
Journal:  Curr Cardiol Rep       Date:  2011-12       Impact factor: 2.931

2.  Regulation of Overnutrition-Induced Cardiac Inflammatory Mechanisms.

Authors:  Rukhsana Gul; Vincent G Demarco; James R Sowers; Adam Whaley-Connell; Lakshmi Pulakat
Journal:  Cardiorenal Med       Date:  2012-07-24       Impact factor: 2.041

3.  Current perspectives on treatment of hypertensive patients with chronic obstructive pulmonary disease.

Authors:  Dipak Chandy; Wilbert S Aronow; Maciej Banach
Journal:  Integr Blood Press Control       Date:  2013-07-09

4.  The Rise and Fall of Hypertension: Lessons Learned from Eastern Europe.

Authors:  Agata Bielecka-Dabrowa; Wilbert S Aronow; Jacek Rysz; Maciej Banach
Journal:  Curr Cardiovasc Risk Rep       Date:  2011-01-06

5.  Lipids, blood pressure, kidney - what was new in 2011?

Authors:  Marcin Barylski; Jolanta Małyszko; Jacek Rysz; Michał Myśliwiec; Maciej Banach
Journal:  Arch Med Sci       Date:  2011-12-30       Impact factor: 3.318

6.  The effects of statins on blood pressure: current knowledge and future perspectives.

Authors:  Manfredi Rizzo; Giuseppe Montalto; Maciej Banach
Journal:  Arch Med Sci       Date:  2012-02-29       Impact factor: 3.318

7.  Reduction in atherosclerotic events: a retrospective study in an outpatient cardiology practice.

Authors:  Anthony D Mercando; Hoang M Lai; Wilbert S Aronow; Phoenix Kalen; Harit V Desai; Kaushang Gandhi; Mala Sharma; Harshad Amin; Trung M Lai
Journal:  Arch Med Sci       Date:  2012-02-29       Impact factor: 3.318

8.  Commentary on recent guidelines for treating hypertension.

Authors:  Wilbert S Aronow
Journal:  Arch Med Sci       Date:  2014-12-22       Impact factor: 3.318

Review 9.  Prevention of sudden cardiac death in patients with chronic kidney disease.

Authors:  Beata Franczyk-Skóra; Anna Gluba; Maciej Banach; Dariusz Kozłowski; Jolanta Małyszko; Jacek Rysz
Journal:  BMC Nephrol       Date:  2012-12-03       Impact factor: 2.388

10.  The decline effect in cardiovascular medicine: is the effect of cardiovascular medicine and stent on cardiovascular events decline over the years?

Authors:  Moo-Sik Lee; Andreas J Flammer; Amir Lerman
Journal:  Korean Circ J       Date:  2013-07       Impact factor: 3.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.